GC
ARQT icon

Guggenheim Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Guggenheim Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Sell
42,255
-979
-2% -$22.8K 0.01% 978
2026
Q1 		$1.02M Buy
43,234
+10,722
+33% +$274K 0.01% 989
2025
Q4 		$944K Buy
+32,512
New +$832K 0.01% 983
2023
Q2 		– Sell
-10,531
Closed -$116K – 1869
2023
Q1 		$116K Buy
10,531
+234
+2% +$3.38K ﹤0.01% 1868
2022
Q4 		$152K Sell
10,297
-1,598
-13% -$27.9K ﹤0.01% 1840
2022
Q3 		$228K Sell
11,895
-121
-1% -$2.74K ﹤0.01% 1750
2022
Q2 		$256K Sell
12,016
-250
-2% -$5.13K ﹤0.01% 1847
2022
Q1 		$236K Buy
12,266
+1,544
+14% +$26.1K ﹤0.01% 1980
2021
Q4 		$222K Buy
+10,722
New +$213K ﹤0.01% 1997

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Guggenheim Capital's ARQT Position: Q2 2026 in Review

Guggenheim Capital reduced its Arcutis Biotherapeutics (ARQT) stake by 2.3% in Q2 2026, selling an estimated $22.8K and leaving 42,255 shares worth $1.11M. The position accounts for 0.01% of the portfolio, ranked #978.

Guggenheim Capital first reported a position in ARQT in Q4 2021 and has held it in 9 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Guggenheim Capital held 42,255 shares of Arcutis Biotherapeutics worth $1.11M as of Q2 2026.
  • Guggenheim Capital sold 979 Arcutis Biotherapeutics shares in Q2 2026, an estimated $22.8K.
  • Arcutis Biotherapeutics made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #978 holding.
  • Guggenheim Capital first reported a position in Arcutis Biotherapeutics in Q4 2021 and has held it in 9 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.